期刊文献+

HPLC法检测大鼠血浆中吡非尼酮的浓度及其药动学研究 被引量:2

HPLC determination of pirfenidone in rat plasma and its pharmacokinetics
原文传递
导出
摘要 目的:建立大鼠血浆吡非尼酮检测的高效液相色谱方法,研究吡非尼酮的药代动力学。方法:血浆经乙酸乙酯,采用ZORBAX SB-C18色谱柱;流动相为乙腈-水-0.1%TFA(三氟乙酸),流速为1.0 mL·min-1;检测波长为318(0~8 min)、246nm(8~10 min)。6只雄性大鼠单剂量灌胃给予15 mg.kg-1吡非尼酮,分别在给药后多点尾静脉采血;用该方法检测血浆中吡非尼酮的浓度。用DAS(数据采集系统)计算药代动力学参数。结果:吡非尼酮浓度在0.025~4.00 mg·L-1范围内线性关系良好(r=0.999 9);定量下限为0.025 mg·L-1;低、中、高3个浓度的相对回收率分别为(100.40±4.66)%、(102.17±4.02)%和(101.12±2.89)%;日内RSD分别为4.6%,3.9%,2.9%,日间RSD分别为5.5%,4.8%,3.7%。大鼠吡非尼酮灌胃后,血浆吡非尼酮在0.39 h达到1.69 mg·L-1的峰值浓度,血浆半衰期为2.21 h。吡非尼酮在大鼠体内符合一级吸收的二室模型。结论:本方法准确可靠、简便快速,适用于大鼠血浆吡非尼酮浓度的测定及其药代动力学研究。 Objective:To develop an HPLC method for the determination of pirfenidone in rat plasma and study its pharmacokinetics. Methods:The plasma was extracted by ethyl acetate. The analytical column was packed with ZORBAX SB -C18. The mobile phase were acetonitrile -water- 0. 1% trifluoroacetic acid at the flow rate of 1.0 mL· min-1. The UV detection wavelength was 318 nm (0 -8 min) ,246 nm (8 - 10 rain). Six Wistar male rats were given a single 20 mg·kg^-1 oral dose of pirfenidone. Blood samples were collected from the tail vein at different time points after oral administration. The concentration of pirfenidone in plasma were detected by this HPLC methods. The pharmacokinetic parameters were analyzed by DAS program. Results: Excellent liner relationship was obtained from the range of 0. 025 mg·kg^-1 to 4. 00 mg·kg^-1( r = 0. 999 9 ), the limit determination of pirfenidone was 0. 025 mg·kg^-1 The relative recoveries were ( 100.4± 4.7 ) % , ( 102.2 ±4.0) % and ( 101.1± 2.9) % respectively at three concentrations, the intra -day RSDs were 4. 6% ,3.9% and 2. 8% and inter -day RSDs were 5.5 % ,4. 8 % and 3.7 % respectively. After oral administration of pirfenidone, the maximum plasma concentration of pirfenidone was 1.69 mg·kg^-1 and the time to reach this value was 0. 39 h. the halflife was 2.21 h. Pirfenidone was fitted the two -compartment model with the first absorption. Conclusion:The method is accurate, simple, rapid and can be used to determine the pirfenidone concentration in rat plasma and for study of its pharmacokinetics.
出处 《药物分析杂志》 CAS CSCD 北大核心 2012年第2期202-205,共4页 Chinese Journal of Pharmaceutical Analysis
关键词 高效液相色谱法 吡非尼酮 抗纤维化新药 生物样品 血药浓度 药代动力学 HPLC pirfenidone against fibrosis new drugs biological sample plasma drug concentration pharmacokinetics
  • 相关文献

参考文献3

二级参考文献57

  • 1张晓岚,王占魁,姜慧卿.氧化应激与肝纤维化[J].临床肝胆病杂志,2007,23(3):226-229. 被引量:24
  • 2Raghu G, Johnson W, Lockhart D. Trearment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone. Am J Respir Crit Care Med, 1999,159 (4) : 1061.
  • 3William AG, Mark B, James T. Effect of pirfenidone on the pulmonary fibrosis of Hermansky - Pudlak syndrome. Mol Genet Metab, 2002,76 (3) :234.
  • 4Bataller R,Brenner DA.Liver fibrosis[J].J Clin Invest,2005,115(2):209-218.
  • 5Ismail MH,Pinzani M.Reversal of liver fibrosis[J].Saudi J Gastroenterol,2009,15(1):72-79.
  • 6Al-Bayati MA,Xie Y,Mohr FC,et al.Effect of pirfenidone against vanadate-induced kidney fibrosis in rats[J].Biochem Pharmacol,2002,64(3):517-525.
  • 7Van Erp C,Irwin NG,Hoey AJ.Long-term administration of pirfenidone improves cardiac function in mdx mice[J].Muscle Nerve,2006,34(3):327-334.
  • 8Oku H,Shimizu T,Kawabata T,et al.Antifibrotic action of pirfenidone and prednisolone:different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis[J].Eur J Pharmacol,2008,590(1-3):400-408.
  • 9Grizzi F.Pirfenidone:a potential therapeutic option in the treatment of liver fibrosis[J].Clin Exp Pharmacol Physiol,2009,36(10):961-962.
  • 10Regulatory watch:First drug for idiopathic pulmonary fibrosis approved in Japan[J].Nat Rev Drug Discov,2008,7(12):966-967.

共引文献14

同被引文献21

  • 1罗心平,施海明,倪唤春,朱军,王彩萍,李剑,范维琥.负荷剂量的氯吡格雷在38例急性心肌梗死直接支架术中的应用[J].中国新药与临床杂志,2004,23(10):667-670. 被引量:8
  • 2Cavu soglu, Erdal, Cheng,et aL Clopidogrel in the Management of Isch emic Heart Disease[J]. HEART DISEASE,2003,5(2) :144-152.
  • 3FURMAN MI, KRUEGER LA, LINDEN MD,et al. GP lI b-lll a amago- nists reduce thromboinflammatory processes in patients with acute coro- nary syndromes undergoing percutaneous coronary int6rvention [ J . J Thromb Haemost,2005,3 (2) : 312 -320.
  • 4Lain es se A, Ozalp Y, Wong H, et al. Bioequivalen ce study of clopi- dogrel bis ulf at e film-coat ed t abl et s[J]. Ar'zneimit t elf orschung, 2004,54(9a) :600-604.
  • 5Robin son A, Hil lis J, Neal C, e t aL T he validat ion of a bioanalytical method for the det ermin at ion of cl opid ogr el in hum an plasma[ J]. Jou real of Chromatography B ,2007,848:344-354.
  • 6S. S. Singh et al. Estimation of caxboxylic acid metabolite of clopidogrel in Wistar rat plasma by I-[PLC and it applioation to a pharmacokinetic study[J]. Chr omatogr B ,2005,821 : 173-180.
  • 7Karimi-Shah BA,Chowdhury BA.Forced vital capacity in idiopathic pulmonary fibrosis-FDA review of pirfenidone and nintedanib[J].N Engl J Med,2015,372(13):1189-1191.
  • 8Cottin V,Maher T.Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis[J].Eur Respir Rev,2015,24(135):58-64.
  • 9Duck A,Pigram L,Errhalt P,et al.IPF care:a support program for patients with idiopathic pulmonary fibrosis treated with pirfenidone in Europe[J].Adv Ther,2015,32(2):87-107.
  • 10Chen JF,Liu H,Ni HF,et al.Improved mitochondrial function underlies the protective effect of pirfenidone against tubulointerstitial fibrosis in 5/6 nephrectomized rats[J].Plos One,2013,8(12):e83593.

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部